Employers are spending more on GLP-1s than ever before, and I believe many of them are actually paying for weight gain.
Processing Content
GLP-1s have kicked employer healthcare spending into overdrive, with many reporting that covering GLP-1s had a "significant" impact on the health plan's prescription drug spending. Some are willing to pay the price, betting that treating obesity now avoids the higher costs of managing diabetes, hypertension and musculoskeletal conditions down the line.
The logic is reasonable, but the reality is more complicated. A medication that can cost thousands a year is an investment. But when patients abandon that medication within six months? It's a waste. And without wraparound clinical support, the data shows more than half abandon their treatment plan within a year.
Read more: Ready for complex open enrollment questions? AI agents can help
The value of GLP-1 spending hinges on two things: whether patients can stay on their medication long enough to achieve results, and whether they can sustain those results if they stop. Research from the Institute for Clinical and Economic Review (ICER) confirms that pairing GLP-1s with lifestyle modifications — nutrition guidance, coaching, and behavior change support — leads to substantial weight loss and reduced cardiometabolic risk.
Without lifestyle support, few employers will see the workforce health benefits they're paying for. Worse, they may see the opposite: users who lose lean muscle mass and regain weight after discontinuation. The painful irony? Employers end up paying for poor outcomes.
GLP-1 use will likely only increase. In the last few months, manufacturers have cut GLP‑1 prices under intense political pressure and growing competition — from Trump's TrumpRx deal to cash‑pay discounts — as the arrival of oral GLP-1s for weight loss are accelerating accessibility on a massive scale. In the first four weeks of 2026, 170,000 patients took Novo's oral GLP-1, making it potentially the fastest pharmaceutical launch in history.
And for the 81% of large employers who haven't found a financially viable path to cover GLP-1s, the risk takes a different form. Employees are seeking out these medications through fragmented cash-pay channels — often without adequate clinical oversight, no coordination with their care team, and no employer visibility into safety or outcomes. These employers don't need to be convinced that GLP-1s matter. They need more affordable, flexible pathways to provide high-quality obesity care, with real clinical infrastructure behind it.
Read more: Retirement confidence slips as costs and debt weigh on workers
The care gap costing employers millions
More than half of people who start a GLP-1 stop within a year. That's not enough time to achieve meaningful health improvements or justify the investment. The question employers should be asking isn't whether to cover GLP-1s — it's what happens after the prescription is written.
Of the 19% of large employers who cover GLP-1s for weight loss, only a third require coaching or lifestyle support. Yet there's often a gap between when someone leaves the doctor's office, and when they fill a GLP-1 prescription. And there's a bigger gap between filling the prescription, and staying on it long enough to see results. In the space between doctors visits, motivation fades, side effects go unmanaged and treatment plans lose momentum. Without coordinated support outside the exam room, employees frequently plateau early, miss doses, discontinue on their own, or regain weight, undercutting the entire investment.
Not everyone needs a GLP-1. Some can be effectively supported with behavior change alone. But for those who do start medication, the evidence is clear: Structured lifestyle support is what separates a prescription from an outcome. Too many employers treat GLP-1 coverage as a set-it-and-forget-it decision, which often results in a set-it-and-regret-it situation.
The smarter approach is to treat it as an ongoing strategy, using claims data, persistence rates and engagement metrics to identify what's working, catch early discontinuation signals, and adjust benefit design over time before costs spiral. Employers should also look for partnerships that tie payment to outcomes, not just utilization. If a program isn't producing clinically meaningful results, employers shouldn't be bearing the full cost.
Read more: Tom Brady's new play: Making GLP-1s affordable for healthcare workers
Not all access is created equal
As cash-pay options proliferate, the safety question gets more urgent. We've already seen direct-to-consumer prescribers turn to compounded oral medications; products that lack FDA approval and don't carry the same safety, quality, or effectiveness assurances as approved drugs. While the FDA has recently taken legal action against compounders, employees aren't waiting; they're buying these medications now, often without any guidance from their employer or provider.
Whether GLP-1s are covered on formulary or accessed through cash-pay channels, employers have a responsibility to steer their workforce toward FDA-approved, clinically supervised pathways, protecting employees from the risks of an unregulated market. Employers don't need to choose between access and safety, but they do need to be intentional about which pathways they offer.
GLP-1s are too impactful to squander. The employers who will get the most value from GLP-1s aren't the ones who simply add coverage, they're the ones building flexible strategies with clinical rigor and lifestyle support as the constant.
